


Reverse Translation Crowd Sourcing Results

Sree Kasichayanula, PhD
Karthik Venkatakrisnan, PhD

Reverse Translation Symposium, ASCPT Annual Meeting
March 18th, 2017

Q1) Please identify your primary sector of affiliation


N= 68



Other: None

Q2) What function(s) do you represent?


N= 68



Other: Precision-medicine Methodologist, Statistician, Translational medicine, Physician


Q3) Is there an expectation or mandate within your organization that you will leverage prior internal/external clinical data to inform early clinical development?

N= 68




Q4) Does your organization approach “knowledge capture” through models (e.g. platform models, disease models, systems models) that can be re-cycled for many projects?

N= 67




Q5) Does your organization regularly review emerging internal/external data from clinical trials in cross functional setting (pre-clinical, pharmacometrics/Modeling and Simulations, biomarkers and physician-scientist) to inform clinical development strategies?

N= 68




Q6) Do you apply modeling and simulation paradigms that leverage data from marketed/late stage molecules to inform development of molecules that share related MoA?

N= 68




Q7) Do you apply modeling and simulation paradigms that leverage data from marketed/late stage molecules to inform development of molecules that are being developed for the same disease?

N= 68




Q8) Do you encourage your discovery teams to use pertinent clinical data with an eye toward optimizing discovery of new molecular entities?

N= 65



Q9) Do you use real world data e.g., electronic medical records, biobanks, registries, observational data, adverse event databases to inform development of target product profile and/ or design of clinical studies?

N= 68



Acknowledgments

- Lisa Williamson (ASCPT)
- Amin Rostami-Hodjegan
- Anne Heatherington
- John Gibbs
- Nicholas Tatonetti
- Survey participants
 - Please continue participating in the survey